RMIT-BITS Pilani Joint PhD Launched for Life Sciences

BITS RMIT Joint PhD in Life Sciences Launches With Telangana: India Australia Doctorates for 2026

Naman Mittal logo

Naman Mittal

| Updated On - Aug 11, 2026

RMIT and BITS Pilani launched an Industry-Integrated PhD on August 4, 2026. Telangana Life Sciences co-designed the doctoral route with the two universities. Life sciences professionals at Hyderabad GCCs can earn a PhD while working. The route replaces the campus-only PhD with joint industry-academia supervision.

  • Life sciences staff at Hyderabad GCCs, including Sandoz, Novartis, Sanofi, Bristol Myers Squibb, MSD, Opella, Align Technology and Thermo Fisher Scientific can be nominated by their employers.
  • Research topics come from the sponsor firm’s live business problems. RMIT and BITS Pilani share academic supervision on every project.
  • Telangana Minister D Sridhar Babu framed the launch as a bid to close India’s research spending gap versus China and the US.

The new track builds on an existing BITS Pilani-RMIT joint PhD scholarship that already sends Indian scholars to Melbourne with a full RMIT tuition waiver and an Australian stipend. The life sciences programme extends that model to mid-career professionals inside India’s largest pharma corridor.

Also Read, 


What the Industry-Integrated PhD Actually Changes

Traditional Indian PhDs run inside a university lab on a supervisor’s chosen problem. The new route flips that arrangement. The sponsor company nominates the research problem. RMIT and BITS Pilani co-supervise the work. The scholar stays on the GCC payroll throughout.

The stated goal is commercially usable research and faster technology transfer. That means patents, product improvements and process fixes tied to a real product line. RMIT Vice-Chancellor Alec Cameron said the collaboration reflects "a collective belief in the power of research and education to improve lives".

What it means for Indian Students: This is not a route for fresh masters graduates targeting an Australia PhD. It is built for scientists already working inside a sponsoring GCC. Freshers should target the standard BITS-RMIT joint PhD scholarship on the university portal, not the industry cohort.


Which Companies Are Sponsoring the First Scholars

Eight global life sciences employers were named at the Hyderabad launch. Each is expected to nominate employees for doctoral work aligned with its India R&D roadmap.

Sponsoring Company India Focus Area
Sandoz Generics and biosimilars
Novartis Innovative medicines, Hyderabad GCC
Sanofi Vaccines and specialty care
Bristol Myers Squibb Oncology and immunology research
MSD Vaccines, oncology, digital science
Opella Consumer healthcare
Align Technology Medical devices, orthodontics
Thermo Fisher Scientific Analytical instruments, biosciences

Telangana Life Sciences CEO Dr Sarvesh Singh, BITS Group Vice-Chancellor Prof V Ramgopal Rao and RMIT Deputy Vice-Chancellor Tim Marshall all attended. Their presence signals that the state government treats the programme as central to Hyderabad’s R&D positioning.


How the Existing RMIT-BITS Joint Scholarship Works

The industry-integrated launch sits on top of a pre-existing joint PhD scholarship that BITS Pilani and RMIT already run. That scholarship pays a monthly stipend of INR 45,800 to scholars entering with a master’s degree. Integrated first-degree holders receive INR 42,800 during coursework and INR 45,800 after.

Selected candidates also get a full RMIT tuition fee waiver for the entire enrolment. Scholars travel to Melbourne for up to one year of the PhD, with an Australian stipend during that stay. Every project has one advisor from each university.

Note: An INR 45,800 monthly PhD stipend paired with a full RMIT tuition waiver is competitive with a first-year Australian PhD offer. The Melbourne year removes the biggest Indian doctoral drawback, hands-on time in a global lab, without asking the scholar to pay tuition or a full visa cost.


Why Hyderabad and Why the Launch Lands Now

Hyderabad is India’s largest pharma manufacturing corridor and hosts a fast-growing set of GCCs for global drug makers. Telangana Minister D Sridhar Babu said India "invests barely one-fourth of China’s and less than one-fifth of the United States’ research intensity". The state framed the programme as a direct response to that gap.

The launch also lands as Australia deepens education ties with India. RMIT already offers Indian dual degrees through the BITS-RMIT Higher Education Academy. This is the doctoral extension of that same pipeline.


How Do Indian Professionals Apply for the Programme?

The industry-integrated cohort is not a public open call. Candidates must be nominated by a sponsoring GCC that has signed on to the programme. Direct applicants should route interest through their employer’s R&D or HR leadership.

For the open BITS-RMIT joint PhD scholarship, applications run through the dedicated portal at bitsrmit.edu.in. Each cycle lists live research projects with named supervisors and specific eligibility tags, typically a B.Tech or M.Tech in the project’s discipline.


The Industry-Integrated PhD is a bet on turning India’s largest pharma cluster into a global research node. For a mid-career Indian scientist at a Hyderabad GCC, the offer is unusual. It combines a doctorate, a foreign co-supervisor and continued salary in one package. The next cohort intake window is expected to be announced through the sponsor companies and BITS Pilani in the coming months.

Action Plan for Indian Applicants

  1. Check if your current employer sits on the eight-company sponsor list above.
  2. Approach your R&D or HR leadership and ask if a doctoral nomination is on the internal roadmap.
  3. For open-market applicants, track the bitsrmit.edu.in portal for the next research project listing.
  4. Prepare a research statement tied to a real industry problem, not a purely academic thesis.
  5. Line up an English writing sample and updated CV before the next intake window opens.

Keep an Eye On: Watch the bitsrmit.edu.in portal for the next research project listing after the August 2026 launch, and confirm with your sponsoring GCC on nomination timelines for the 2027 intake.

Also Read, 

Comments


No Comments To Show